CN114450068A - 用于治疗急性神经炎性损伤的方法和剂 - Google Patents

用于治疗急性神经炎性损伤的方法和剂 Download PDF

Info

Publication number
CN114450068A
CN114450068A CN202080067788.1A CN202080067788A CN114450068A CN 114450068 A CN114450068 A CN 114450068A CN 202080067788 A CN202080067788 A CN 202080067788A CN 114450068 A CN114450068 A CN 114450068A
Authority
CN
China
Prior art keywords
antibody
hours
seq
sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080067788.1A
Other languages
English (en)
Chinese (zh)
Inventor
布莱恩·W·齐格拉尔
大卫·T·克罗
加里·卢埃林·雷德里希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inprecit Bioscience Co ltd
Original Assignee
Inprecit Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902642A external-priority patent/AU2019902642A0/en
Application filed by Inprecit Bioscience Co ltd filed Critical Inprecit Bioscience Co ltd
Publication of CN114450068A publication Critical patent/CN114450068A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202080067788.1A 2019-07-25 2020-07-24 用于治疗急性神经炎性损伤的方法和剂 Pending CN114450068A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902642 2019-07-25
AU2019902642A AU2019902642A0 (en) 2019-07-25 Methods and agents for treating acute neuroinflammatory injury
PCT/US2020/043619 WO2021016601A1 (en) 2019-07-25 2020-07-24 Methods and agents for treating acute neuroinflammatory injury

Publications (1)

Publication Number Publication Date
CN114450068A true CN114450068A (zh) 2022-05-06

Family

ID=74192699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080067788.1A Pending CN114450068A (zh) 2019-07-25 2020-07-24 用于治疗急性神经炎性损伤的方法和剂

Country Status (8)

Country Link
US (1) US20220249610A1 (enExample)
EP (1) EP4003518A4 (enExample)
JP (1) JP2022541646A (enExample)
KR (1) KR20220040478A (enExample)
CN (1) CN114450068A (enExample)
AU (1) AU2020316519A1 (enExample)
IL (1) IL290046A (enExample)
WO (1) WO2021016601A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144141A1 (en) * 2018-01-22 2019-07-25 UNIVERSITY OF VIRGINIA PATENT FOUNDATION d/b/a UNIVERSITY OF VIRGINIA LICENSING & VENTURE System and method for automated detection of neurological deficits
CN116367858A (zh) * 2020-09-10 2023-06-30 隐式生物科技有限公司 用于治疗心肌梗塞的治疗方法和试剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088902A2 (en) * 2007-01-17 2008-07-24 Yale University Attenuation of the adaptive immune response
WO2018191786A1 (en) * 2017-04-21 2018-10-25 Implicit Bioscience Pty Ltd Cd 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
CA2609262A1 (en) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088902A2 (en) * 2007-01-17 2008-07-24 Yale University Attenuation of the adaptive immune response
WO2018191786A1 (en) * 2017-04-21 2018-10-25 Implicit Bioscience Pty Ltd Cd 14 antagonist antibodies for treating neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QING WANG等: "The inflammatory response in stroke", JOURNAL OF NEUROIMMUNOLOGY, 13 March 2007 (2007-03-13), pages 53 *
RUDI BESCHORNER等: "CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury", ACTA NEUROPATHOL, vol. 103, no. 6, 1 June 2002 (2002-06-01), pages 541, XP038164607, DOI: 10.1007/s00401-001-0503-7 *

Also Published As

Publication number Publication date
JP2022541646A (ja) 2022-09-26
AU2020316519A1 (en) 2022-02-24
US20220249610A1 (en) 2022-08-11
IL290046A (en) 2022-03-01
KR20220040478A (ko) 2022-03-30
EP4003518A4 (en) 2023-07-12
WO2021016601A1 (en) 2021-01-28
EP4003518A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
US12006364B2 (en) Anti-CD100 antibodies and methods for using the same
JP7480197B2 (ja) 抗ｔｒｅｍ１抗体及びその使用方法
JP7725185B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
CN107106679B (zh) 抗trem2抗体及其使用方法
KR20250166355A (ko) 안과 질환의 치료
JP6863892B2 (ja) 脳卒中を治療又は予防する方法
CN113039203A (zh) 通过破坏siglec型抗原的顺式配体结合调节自身免疫的方法
JP6865581B2 (ja) 神経学的疾患又は神経変性疾患に有用な新規抗体
CN114450068A (zh) 用于治疗急性神经炎性损伤的方法和剂
KR20190039134A (ko) Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도
CN117412767A (zh) C-x-c基序趋化因子受体6（cxcr6）结合分子及其使用方法
CN114423788B (zh) 抗nrp1a抗体及其用于治疗眼或眼部疾病的用途
KR102096509B1 (ko) 항-Tspan12 항체 또는 그의 항원-결합 단편, 및 그의 용도
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
KR102959210B1 (ko) 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도
TW201906865A (zh) 預防及治療尿失禁之方法
US12617848B2 (en) Methods of treating ocular pathologies using bifunctional molecules that target growth factors
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
CN111108121A (zh) Il-20拮抗剂治疗眼病的用途
HK1243006B (en) Anti-trem2 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination